PHATHOM PHARMACEUTICALS INC (PHAT) Stock Price, Quote, News and Overview
NASDAQ:PHAT - Nasdaq - US71722W1071 - Common Stock - Currency: USD
PHAT Quote, Performance and Key Statistics
PHATHOM PHARMACEUTICALS INC
NASDAQ:PHAT (1/24/2025, 4:08:12 PM)
After market: 6.9 0 (0%)6.9
-0.27 (-3.77%)
The current stock price of PHAT is 6.9 USD. In the past month the price decreased by -9.33%. In the past year, price decreased by -0.58%.
PHAT Latest News, Press Releases and Analysis
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
Citizen Petition seeks correction of expiration date for New Chemical Entity (NCE) exclusivity on VOQUEZNA (vonoprazan) tablets Orange Book listingsPhathom...
Phathom Pharmaceuticals is Now Oversold (PHAT)
PHAT Crosses Below Key Moving Average Level
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential quarterly...
PHAT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 77.23 | 745.61B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 29.62 | 390.70B | ||
| JNJ | JOHNSON & JOHNSON | 14.7 | 353.49B | ||
| MRK | MERCK & CO. INC. | 16.06 | 241.71B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.13 | 214.16B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.4 | 199.87B | ||
| PFE | PFIZER INC | 10.11 | 147.85B | ||
| SNY | SANOFI-ADR | 12.56 | 131.58B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 51 | 121.02B | ||
| ZTS | ZOETIS INC | 29.27 | 76.07B | ||
| GSK | GSK PLC-SPON ADR | 8.34 | 69.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.65 | 41.18B |
Related stock screener links
About PHAT
Company Profile
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 452 full-time employees. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Company Info
PHATHOM PHARMACEUTICALS INC
100 Campus Drive, Suite 102
Florham Park NEW JERSEY 07932 US
CEO: Terrie Curran
Employees: 452
Company Website: https://www.phathompharma.com/
Investor Relations: https://investors.phathompharma.com/
Phone: 18777428466
PHAT FAQ
What is the stock price of PHAT?
The current stock price of PHAT is 6.9 USD.
What is the symbol for PHATHOM PHARMACEUTICALS INC stock?
The exchange symbol of PHATHOM PHARMACEUTICALS INC is PHAT and it is listed on the Nasdaq exchange.
On which exchange is PHAT stock listed?
PHAT stock is listed on the Nasdaq exchange.
Is PHAT a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PHAT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PHAT.
Does PHAT stock pay dividends?
PHAT does not pay a dividend.
What is the Price/Earnings (PE) ratio of PHAT?
PHAT does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.69).
What is the Short Interest ratio of PHAT stock?
The outstanding short interest for PHAT is 29.27% of its float.
PHAT Technical Analysis
PHAT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHAT. Both the profitability and financial health of PHAT have multiple concerns.
PHAT Financial Highlights
Over the last trailing twelve months PHAT reported a non-GAAP Earnings per Share(EPS) of -5.69. The EPS decreased by -48.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.7% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PHAT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to PHAT. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -46.9% and a revenue growth 12635.7% for PHAT